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Staphylococcus aureus is the leading cause of blood-
stream, lower respiratory tract, skin, and soft tis-
sue infections in the United States (Klevens et al., 
2007). Methicillin-resistant S. aureus (MRSA) 
strains are isolated in more than half of all com-
munity and hospital infections (Klevens et al., 
2008). MRSA strains harbor methicillin resis-
tance genes, rendering the entire class of -lactam 
antimicrobials obsolete as therapeutic agents 
(Berger-Bächi, 1994). Some MRSA isolates also 
acquired resistance to vancomycin, the anti-
biotic of last resort. These strains threaten a re-
turn to the preantibiotic era (Chang et al., 2003). 
Thus, there is an urgent need for vaccines that 
protect against staphylococcal infection.
S. aureus infection in humans is not associated 
with the generation of protective immunity,   
as patients often suffer recurrent bouts of skin   
and soft tissue infections (Lowy, 1998). Recent   
advances described several mechanisms for staph-
ylococcal  escape  from  innate  host  defenses   
(de Haas et al., 2004; Rooijakkers et al., 2005; 
Thammavongsa et al., 2009); however, the mo-
lecular events underlying the escape from adap-
tive  immune  responses  during  staphylococcal 
infection are not known. Human diseases caused 
by S. aureus can be recapitulated in animals. 
In particular, experimental infections of the lung, 
skin, or soft tissues and internal organs have been 
established in mice (Bubeck Wardenburg et al., 
2008; Cheng et al., 2009). Using these models 
and molecular genetics approaches, staphylococ-
cal protein A (SpA), a cell wall–anchored surface 
protein (Sjöquist et al., 1972), was identified as a 
crucial virulence factor for lung infections, septi-
cemia, and abscess development (Palmqvist et al., 
2002; Gómez et al., 2004; Cheng et al., 2009).
The vast majority of clinical S. aureus isolates 
express SpA (Forsgren, 1970; Shopsin et al., 1999), 
which binds to the Fc portion of most Ig sub-
classes (Jensen, 1958; Lindmark et al., 1983), VH3 
type B cell receptors (Sasso et al., 1989), von Wil-
lebrand factor (vWF; Hartleib et al., 2000), and 
TNFR1 (Gómez et al., 2004). Interaction of SpA 
with B cell receptors (IgM) leads to clonal expan-
sion and subsequent cell death of B cell populations 
with effects on adaptive and innate immune re-
sponses (Forsgren and Quie, 1974; Forsgren 
et al., 1976; Goodyear and Silverman, 2004; 
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The current epidemic of hospital- and community-acquired methicillin-resistant Staphylo-
coccus aureus (MRSA) infections has caused significant human morbidity, but a protective 
vaccine is not yet available. Prior infection with S. aureus is not associated with protective 
immunity. This phenomenon involves staphylococcal protein A (SpA), an S. aureus surface 
molecule that binds to Fc of immunoglobulin (Ig) and to the Fab portion of VH3-type  
B cell receptors, thereby interfering with opsonophagocytic clearance of the pathogen and 
ablating adaptive immune responses. We show that mutation of each of the five Ig-binding 
domains of SpA with amino acid substitutions abolished the ability of the resulting variant 
SpAKKAA to bind Fc or Fab VH3 and promote B cell apoptosis. Immunization of mice with 
SpAKKAA raised antibodies that blocked the virulence of staphylococci, promoted opsono-
phagocytic clearance, and protected mice against challenge with highly virulent MRSA 
strains. Furthermore, SpAKKAA immunization enabled MRSA-challenged mice to mount 
antibody responses to many different staphylococcal antigens.
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RESULTS AND DISCUSSION
SpA is a virulence factor for lethal S. aureus infections
The contribution of the spa gene toward lethal S. aureus 
challenge has thus far not been appreciated. To address 
this, we generated the isogenic spa deletion variant S. 
aureus Newman spa. After intraperitoneal challenge 
with 2 × 108 CFU of wild-type S. aureus Newman, 
60% of animals succumbed to challenge. In contrast, 
animals infected with the isogenic mutant resulted in 
only 25% mortality (Fig. S1 A). In addition, the spa mu-
tant displayed a consistent survival defect when exam-
ined in naive mouse blood (see Fig. 3 D). These results 
suggest that SpA is a crucial virulence factor for lethal 
infections of S. aureus in mice.
SpA-DKKAA cannot bind to immunoglobulin and trigger   
B cell apoptosis
Guided by amino acid homology, the triple -helical bundle 
structure of Ig binding domains (Deisenhofer, 1981), and their 
atomic interactions with Fab VH3 (Graille et al., 2000) or Fc 
(Gouda et al., 1998), we selected glutamine 9 and 10, as well 
as aspartate 36 and 37, as critical for the association of SpA with 
immunoglobulin (Fig. 1, A and B; and Fig. S2, A and B).   
To test this, substitutions Gln9Lys, Gln10Lys, Asp36Ala, and   
Asp37Ala were introduced into the D domain to generate SpA-
DKKAA (Fig. 1 B). The ability of isolated SpA-D or SpA-DKKAA 
to bind human IgG or IgM was analyzed by affinity chroma-
tography and ELISA (Fig. 1, C and D). Polyhistidine-tagged 
SpA-D, as well as full-length SpA, retained human IgG on Ni-
NTA, whereas SpA-DKKAA or a negative control (sortase A; 
Mazmanian et al., 1999) did not (Fig. 1, C and D). A similar 
result was observed with vWF (Hartleib et al., 2000), which, 
along with TNFR1 (Gómez et al., 2004), can also bind SpA 
via glutamines 9 and 10 (Gómez et al., 2006; Fig. 1 D). Human 
Ig encompasses 50% VH3-type IgG (Cook and Tomlinson, 
1995). Human Fc and F(ab)2 fragments, as well as IgM, all 
Silverman and Goodyear, 2006). In contrast, SpA binding to 
the Fc of Ig interferes with opsonophagocytic clearance of 
staphylococci by polymorphonuclear leukocytes (Peterson et al., 
1977). SpA is synthesized as a precursor with an N-terminal signal 
peptide and a C-terminal sorting signal for covalent anchoring 
to the cell wall (Schneewind et al., 1992). The N-terminal part 
of mature SpA is comprised of four or five 56–61-residue Ig 
binding domains (Sjödahl, 1977), which fold into triple helical 
bundles connected by short linkers (Deisenhofer, 1981). The 
C-terminal region X is comprised of Xr, a highly repetitive yet 
variable octapeptide, and Xc, a domain of unique sequence 
which abuts the cell wall anchor structure of SpA (Guss et al., 
1984; Schneewind et al., 1995).
As a result of the attribute of simultaneously binding Fc and 
Fab, SpA vaccines with neutralizing antibodies and protective 
immunity have hitherto not been reported (Greenberg et al., 
1989). We wondered whether antibodies that neutralize the   
immunosuppressive properties of SpA could affect the outcome 
of S. aureus infections.
Figure 1.  Generation of a nontoxigenic SpA vaccine. (A) SpA 
of S. aureus Newman and USA300 LAC harbors an N-terminal sig-
nal peptide (white boxes), five Ig binding domains (E, D, A, B, and 
C), variable region X, and C-terminal sorting signal (black boxes). 
(B) Amino acid sequence of the five Ig binding domains, as well as 
nontoxigenic SpA-DKKAA, with the positions of triple -helical bun-
dles (H1, H2, and H3), as well as glutamine (Q, red) 9 and 10 and 
aspartate (D, green) 36 and 37 as indicated. (C) Coomassie blue–
stained SDS-PAGE of SpA, SpA-D, SpA-DKKAA, or sortase A purified 
on Ni-NTA sepharose in the presence or absence of human immu-
noglobulin (hIgG). (D) ELISA examining the association of im-
mobilized SpA, SpA-D, or SpA-DKKAA with human IgG, as well as its 
Fc or F(ab)2 fragments, vWF and IgM. Statistical significance of 
SpA-DKKAA binding to each ligand was compared against SpA-D, 
and SpA-D binding was compared against SpA (n = 3). *, P < 0.05; 
**, P < 0.01. (E) CD19+ B lymphocytes in splenic tissue of 6-wk-old 
BALB/c mice (n = 6) that had been mock immunized or treated 
with SpA-D or SpA-DKKAA were quantified by FACS. Data are the 
means and error bars represent ±SEM. Results in C–E are represen-
tative of three independent analyses.JEM VOL. 207, August 30, 2010  1865
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full-length SpA were higher than those elicited by SpA-D   
(P = 0.0022), which is likely a result of the larger size and re-
iterative domain structure of this antigen (Table I). Neverthe-
less, even SpA elicited lower antibody titers than SpA-DKKAA 
(P = 0.0003), which encompasses only 50 aa of the mature 
520-residue protein. Immunized mice were challenged by in-
travenous inoculation with S. aureus Newman, and the ability 
of staphylococci to seed abscesses in renal tissues was exam-
ined by necropsy 4 d after challenge (Cheng et al., 2009).   
In homogenized renal tissue of mock (PBS/adjuvant) immu-
nized mice, a mean staphylococcal load of 6.46 log10 CFU g1 
was enumerated (Table I). Immunization of mice with SpA or 
SpA-D led to a reduction in staphylococcal load; however, 
SpA-DKKAA–vaccinated animals displayed an even greater 3.07 
log10 CFU g1 reduction of S. aureus Newman in renal tissues 
(P < 0.0001; Table I). Abscess formation in kidneys was   
analyzed by histopathology (Fig. S3 A-H). Mock immunized 
animals harbored a mean of 3.7 (±1.2) abscesses per kidney 
(Table I). Vaccination with SpA-DKKAA reduced the mean 
number of abscesses to 0.5 (±0.4; P = 0.0204), whereas im-
munization with SpA or SpA-D did not cause a significant re-
duction in the number of abscess lesions (Table I). Lesions 
from SpA-DKKAA–vaccinated animals were smaller in size, 
with fewer infiltrating PMNs, and characteristically lacked 
staphylococcal abscess communities (Cheng et al., 2009;   
Fig. S3, A–H). Abscesses in animals that had been immunized 
with SpA or SpA-D displayed the same overall structure of le-
sions in mock immunized animals (Fig. S3, A–H).
We wondered whether SpA-DKKAA immunization could 
protect mice against MRSA strains and selected the USA300 
bound to full-length SpA or SpA-D but not to SpA-DKKAA 
(Fig. 1 D). Injection of SpA-D into the peritoneal cavity of 
mice resulted in B cell expansion followed by apoptotic col-
lapse of CD19+ (or CD45R+) lymphocytes in the spleen tissue 
of BALB/c or C57BL/6 mice (Goodyear and Silverman, 2003; 
Fig. 1 E). B cell superantigen activity was not observed after 
injection with SpA-DKKAA, and TUNEL-staining of splenic 
tissue failed to detect the increase in apoptotic cells that follows 
injection of SpA or SpA-D (Fig. 1 E; and Fig. S2, E–G).
Antibodies against SpA-DKKAA protect against MSSA  
and MRSA infections
Naive BALB/c mice were injected with 50 µg each of puri-
fied  SpA,  SpA-D,  or  SpA-DKKAA  emulsified  in  CFA  and 
boosted with the same antigen emulsified in IFA. IgG re-
sponses to immunization were examined by ELISA with 
SpA-DGGSS and SpA-DKKAA. SpA-DGGSS harbors amino acid 
substitutions at the same positions as SpA-DKKAA; however, 
glutamines 9 and 10 were each replaced with glycine and as-
partic acids 36 and 37 with serine. Similar to SpA-DKKAA, 
SpA-DGGSS does not interact with human IgG (unpublished 
data). It is of note that similar antibody titers were measured 
with SpA-DGGSS and SpA-DKKAA antigen, indicating that the 
four amino acid substitutions do not diminish the reactivity of 
antibodies raised with heterologous antigens (IgG titers against 
SpA-DKKAA vs. SpA-DGGSS, P = 0.8315). After immunization 
of mice with either SpA-D or SpA-DKKAA, we observed a 10-
fold higher titer of SpA-specific antibodies for the nontoxi-
genic variant as compared with the B cell superantigen (P < 
0.0001; Table I). Antibody titers raised by immunization with 
Table I.  Active immunization of mice with SpA vaccines
Antigen Staphylococcal load and abscess formation in renal tissue
Log10 CFU g-1a P valueb Reduction (log10 
CFU g1)c
IgG titerd Number of 
abscessese
P-valueb
S. aureus Newman 
challenge
Mock 6.46 ± 0.25 N/A N/A <100 3.7 ± 1.2 N/A
SpA 3.95 ± 0.56 0.0003 2.51 1,706 ± 370 2.1 ± 1.2 0.3581
SpA-D 4.43 ± 0.41 0.0001 2.03 381 ± 27 1.5 ± 0.8 0.1480
SpA DKKAA 3.39 ± 0.50 <0.0001 3.07 5,600 ± 801 0.5 ± 0.4 0.0204
S. aureus USA300 (LAC) 
challenge
Mock 7.20 ± 0.24 N/A N/A <100 4.0 ± 0.8 N/A
SpA 6.81 ± 0.26 0.2819 0.39 476 ± 60 3.3 ± 1.0 0.5969
SpA-D 6.34 ± 0.52 0.1249 0.86 358 ± 19 2.2 ± 0.6 0.0912
SpA-DKKAA 6.00 ± 0.42 0.0189 1.20 3,710 ± 1147 1.6 ± 0.6 0.0277
SpAKKAA 3.66 ± 0.76 0.0001 3.54 10,200 ± 2476 1.2 ± 0.5 0.0109
aMeans ± SEM of staphylococcal load calculated as log10 CFU g1 in homogenized renal tissues 4 d after infection in cohorts of 15–20 BALB/c mice per immunization.  
A representative of three independent and reproducible animal experiments is shown.
bStatistical significance was calculated with the unpaired two-tailed Students t test and p-values were recorded.
cReduction in bacterial load calculated as log10 CFU g1.
dMeans ± SEM of five randomly chosen serum IgG titers were measured before staphylococcal infection by ELISA using SpA-DKKAA or SpA-DGGSS as antigens.
eHistopathology of hematoxylin-eosin–stained thin-sectioned kidneys from 10 animals. The mean number of abscesses per kidney was recorded and averaged again for the 
final mean ± SEM.1866 Protein A vaccine against MRSA | Kim et al.
SpA-DKKAA antibodies neutralize immunoglobulin binding 
activities of SpA
Rabbits were immunized with SpA-DKKAA, and specific anti-
bodies were purified on SpA-DKKAA affinity column and ana-
lyzed by SDS-PAGE (Fig. 2 A, lane 1). SpA-DKKAA–specific 
IgG was cleaved with pepsin to generate Fc and F(ab)2 frag-
ments (Fig. 2 A, lane 2), the latter of which were repurified by 
affinity chromatography on SpA-DKKAA column (Fig. 2 A, lane 3). 
Binding of human IgG or vWF to SpA or SpA-D was perturbed 
by SpA-DKKAA–specific F(ab)2, indicating that SpA-DKKAA–
derived antibodies can block the Fc- and vWF-binding prop-
erties of SpA (Fig. 2, B and C).
SpAKKAA generates improved protective immune responses
To further improve the vaccine properties for nontoxigenic 
SpA, we generated SpAKKAA, which includes all five Ig binding 
domains with four amino acid substitutions—Gln9Lys, Gln10Lys, 
Asp36Ala, and Asp37Ala—in each of its five domains (E, D, 
LAC isolate for animal challenge (Diep et al., 2006). This 
highly virulent CA-MRSA strain spread rapidly throughout 
the United States, causing significant human morbidity and 
mortality. Compared with adjuvant control mice, SpA-DKKAA–
immunized animals harbored a 1.20 log10 CFU g1 reduction 
in bacterial load of infected kidney tissues. Histopathology 
examination of renal tissue after S. aureus USA300 challenge 
revealed that the mean number of abscesses was reduced from 
4.0 (±0.8) to 1.6 (±0.6; P = 0.0277). In contrast, SpA or 
SpA-D immunization did not cause a significant reduction in 
bacterial load or abscess formation (Table I; and Fig. S3, I–L 
and N–Q).
Figure 2.  Antibodies raised by the nontoxigenic SpA vaccine block 
the association of immunoglobulin and vWF with SpA. (A) Rabbit anti-
bodies raised against SpA-DKKAA were affinity purified on a matrix with  
immobilized antigen and analyzed by Coomassie blue–stained SDS-PAGE 
under reducing conditions (lane 1, -SpA-DKKAA). SpA-DKKAA antibodies were 
treated with pepsin to separate Fc and F(ab)2 (lane 2). The resulting F(ab)2 
fragments were repurified by affinity chromatography on SpA-DKKAA (lane 3). 
(B and C) SpA-DKKAA specific F(ab)2 was added to wild-type SpA, SpA-D,  
or SpA-DKKAA, and the association with human IgG (B; n = 3) or vWF  
(C; n = 3) was measured. Data are the means and error bars represent ±SEM. 
Results in A–C are representative of three independent analyses. *, P < 0.01.
Figure 3.  Full-length nontoxigenic SpA elicits antibodies that stimu-
late opsonophagocytic clearance of staphylococci. (A) Full-length SpAKKAA 
was purified on Ni-NTA sepharose and analyzed by Coomassie blue–stained 
SDS-PAGE. (B) ELISA examining the association of immobilized SpA or  
SpAKKAA with human IgM, IgG, and its Fc or F(ab)2 fragments or vWF (n = 3).  
*, P < 0.01. (C) CD19+ B lymphocytes in splenic tissue of 6-wk-old BALB/c mice 
(n = 5) that had been mock immunized or treated with SpA or SpAKKAA were 
quantified by FACS. (D, Left) Anticoagulated mouse whole blood (lepirudin) 
was incubated with 5 × 105 CFU S. aureus Newman or its isogenic spa variant 
and survival measured (n = 3). (D, Right) Opsonophagocytic clearance of 
staphylococci (5 × 104, 5 × 105, or 5 × 106 CFU) was measured in the presence 
of affinity-purified V10 (V10) or SpAKKAA-specific antibodies in naive mouse 
whole blood (n = 3). *, P < 0.05. Data are the means and error bars represent 
±SEM. Results in A–D are representative of three independent analyses.JEM VOL. 207, August 30, 2010  1867
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matrices with immobilized cognate antigen and injected at a 
concentration of 5 mg × kg1 body weight into the peritoneal 
cavity of BALB/c mice (Table II). 24 h later, antibody titers 
specific for SpA-DKKAA/SpAKKAA were determined in serum 
and animals challenged by intravenous inoculation with S.   
aureus Newman. Passive transfer reduced the staphylococcal load 
in kidney tissues for SpA-DKKAA- (P = 0.0016) or SpAKKAA  
(P = 0.0005)-specific antibodies. On histopathology examina-
tion, both antibodies reduced the abundance of abscess lesions 
in kidneys of mice challenged with S. aureus Newman (Table II). 
Compared with control cohorts treated with nonspecific anti-
body (-V10), animals that had been injected with SpA-specific 
antibodies were protected against the B cell superantigen activ-
ity of SpA (Fig. S2, C and D). In addition, SpA-specific anti-
bodies (2 µg × ml1) induced opsonophagocytic clearance of 
S. aureus Newman inoculated into naive mouse blood (Fig. 3 D) 
and reduced the mortality associated with lethal staphylococcal 
challenge (Fig. S1 C). Together these data reveal that disease 
protection after immunization with SpA-DKKAA or SpAKKAA is 
conferred by antibodies that bind SpA and neutralize its ability 
to bind Ig.
SpAKKAA immunization promotes host antibody response  
to staphylococcal infection
After infection with virulent S. aureus Newman and clearance 
of the pathogen with antibiotic treatment, mice do not de-
velop protective immunity against subsequent infection with 
the same strain (Fig. S3 S). The mean abundance of SpA-
DKKAA–specific IgG in these animals was determined by dot 
blot as 0.20 µg ml1 (±0.04) and 0.14 µg ml1 (±0.01) for in-
fections  caused  by S.  aureus  strains  Newman  and  USA300 
LAC, respectively (Fig. 4 A). A concentration of 4.05 µg ml1 
(±0.88) for SpA-specific IgG was estimated to confer disease 
protection in SpAKKAA- or SpA-DKKAA–immunized mice (P ≤ 
0.05 log10 reduction in staphylococcal CFU g1 renal tissue; 
unpublished data). The mean serum concentration of SpA-
specific IgG in adult healthy human volunteers (n = 16) was 
0.21 µg ml1 (±0.02). Such antibody concentration may not 
be sufficient to generate protection against staphylococcal 
A, B, and C; Sjödahl, 1977). Polyhistidine-tagged SpAKKAA was 
purified by affinity chromatography and analyzed by Coomassie 
blue–stained SDS-PAGE (Fig. 3 A). Unlike full-length SpA, 
SpAKKAA did not bind human IgG, Fc and F(ab)2, IgM, or vWF 
(Fig. 3 B). SpAKKAA failed to display B cell superantigen activity, 
as injection of the variant into BALB/c or C57BL/6 mice did 
not cause a depletion of both CD19+ and CD45R+ B cells in 
splenic tissue (Fig. 3 C; Fig. S2, C and D; and not depicted). 
SpAKKAA immunization generated higher specific antibody titers 
than SpA-DKKAA and provided mice with elevated protection 
against S. aureus USA300 (Table I) or Mu50 challenge (Fig. S3 
U; Mu50 is a Japanese MRSA isolate). 4 d after challenge, 
SpAKKAA-vaccinated animals harbored 3.54 log10 CFU g1  
fewer staphylococci in renal tissues (P = 0.0001) and also 
caused a greater reduction in the number of abscess lesions   
(P = 0.0109; Table I; and Fig. S3, I–R). Furthermore, SpAKKAA 
immunization reduced the mortality of mice that received a   
lethal S. aureus challenge dose (Fig. S1 B).
Staphylococci persist in mouse organ tissues (Cheng et al., 
2009). Over time, abscesses harboring communities of the in-
fectious agent increase in size and eventually rupture, thereby 
releasing staphylococci into circulation. This initiates the for-
mation of new abscesses and precipitates lethal outcomes   
30–60 d after challenge (Cheng et al., 2009). We asked whether 
SpA-DKKAA or SpAKKAA immunization prevents staphylococ-
cal replication over a longer period of time. 15 d after chal-
lenge with S. aureus USA300, immunization with SpA did 
not generate significant protection of animals compared with 
the mock control (P = 0.5817; Table S1). In contrast, immu-
nization with SpA-DKKAA caused a 1.56 log10 CFU g1 reduc-
tion (P = 0.0183), whereas SpAKKAA vaccination reduced the 
load by 2.7 log10 CFU g1 (P = 0.0059). These data suggest 
that antibodies against SpA, generated via active immuniza-
tion using nontoxigenic SpAKKAA, can interfere with bacterial 
persistence in host tissues.
SpA-specific antibodies generate protective immunity
SpAKKAA was used to immunize rabbits. Rabbit antibodies 
specific for SpA-DKKAA or SpAKKAA were affinity purified on 
Table II.  Passive immunization of mice with antibodies against SpA
Antibodya Staphylococcal load and abscess formation in renal tissue
Log10 CFU g1b P valuec Reduction (log10 CFU g1)d IgG titere Number of abscessesf P-valuec
Mock (-V10) 7.10 ± 0.14 N/A N/A <100 4.5 ± 0.8 N/A
-SpA-DKKAA 5.53 ± 0.43 0.0016 1.57 466 ± 114 1.9 ± 0.7 0.0235
-SpAKKAA 5.69 ± 0.34 0.0005 1.41 1,575 ± 152 1.6 ± 0.5 0.0062
 aAffinity-purified antibodies were injected into the peritoneal cavity of BALB/c mice at a concentration of 5 mg × kg1 24 h before intravenous challenge with 1 × 107 CFU  
S. aureus Newman.
bMeans ± SEM of staphylococcal load calculated as log10 CFU g1 in homogenized renal tissues 4 d after infection in cohorts of 15 BALB/c mice per immunization.  
A representative of three independent and reproducible animal experiments is shown.
cStatistical significance was calculated with the unpaired two-tailed Students t test and p-values were recorded.
dReduction in bacterial load calculated as log10 CFU g1.
eMeans ± SEM of five randomly chosen serum IgG titers were measured before staphylococcal infection by ELISA.
fHistopathology of hematoxylin-eosin–stained thin-sectioned kidneys from 10 animals. The mean number of abscesses per kidney was recorded and averaged again for the 
final mean ± SEM.1868 Protein A vaccine against MRSA | Kim et al.
(unpublished data). Mock immunized mice (adjuvant only) 
that had been subjected to USA300 infection developed high-
titer antibodies against the Eap protein as well as low-titer anti-
bodies against Hla, IsdA, IsdB, LukD, LukE, and LukF (Fig. 4 B). 
In response to USA300 challenge, animals that had been immu-
nized with SpAKKAA (IgG titer 2,907 [±357]; P < 0.001, SpAKKAA 
vs. mock) mounted humoral immune responses against every 
antigen examined (Fig. 4 B). With the exception of Eap, IsdA, 
and IsdB antibodies, the serum of SpAKKAA-immunized ani-
mals harbored higher antibody titers against staphylococcal an-
tigens as compared with mice that had been naive at the time 
of challenge (Fig. 4 B).
In summary, S. aureus isolates express SpA, an essential 
virulence factor whose B cell superantigen activity and evasive 
attributes toward opsonophagocytic clearance are required for 
staphylococcal  abscess  formation  and  the  establishment  of   
lethal disease (Cheng et al., 2009). SpA can be thought of as a 
toxin that is essential for pathogenesis and whose molecular 
attributes must be neutralized to achieve protective immunity. 
By generating nontoxigenic variants unable to bind Igs via 
Fc or VH3-Fab domains, we identified SpA-neutralizing   
immune responses as a correlate for protective immunity 
against S. aureus infection. In contrast 
to many methicillin-sensitive strains, 
the  CA-MRSA  isolate  USA300 
LAC is significantly more virulent 
(Cheng et al., 2009). For example, 
immunization of experimental animals 
infection. By comparison, the mean serum concentration of IgG 
specific for diphtheria toxin in human volunteers, 0.68 µg ml1 
(± 0.20), is thought to be within range for protective immu-
nity against diphtheria (Lagergård et al., 1992).
These results are in agreement with a model of immune 
evasion during S. aureus infection. Cell wall–anchored or se-
creted SpA (e.g., 20% of peptidoglycan and attached surface 
protein is released during bacterial division; Ton-That et al., 
1999) activate B cells via IgM receptor cross-linking. Without 
stimuli from specific antigens, activated B cells undergo apop-
tosis, thereby hindering the production of antibody against 
staphylococcal antigens. If so, neutralizing antibodies directed 
against SpA may enable humoral immune responses against 
many different staphylococcal antigens. This was tested by im-
munizing BALB/c mice with SpAKKAA or an adjuvant (alumi-
num hydroxide) control, followed by intravenous challenge 
with a sublethal dose of MRSA strain USA300. Serum samples 
were withdrawn 30 d after MRSA challenge and then ana-
lyzed by immunoblotting with 27 staphylococcal antigens im-
mobilized on a membrane filter (Fig. 4 B). Naive mice, which 
had not been infected with the MRSA strain USA300 LAC, 
did not harbor antibodies against staphylococcal antigens 
Figure 4.  SpAKKAA immunization modi-
fies host immune responses to staphylo-
coccal infection. (A) Human or mouse 
serum antibody titers to diphtheria toxoid 
(CRM197) and nontoxigenic SpAKKAA or SpA-
DKKAA. Human volunteers with a history of 
diphtheria (DTaP) immunization and staphy-
lococcal infection (n = 16), as well as mice 
(n = 20) that had been infected with S. aureus 
Newman or USA 300 LAC or immunized 
with SpAKKAA or SpA-DKKAA, were examined 
by quantitative immunoblot. (B) Cohorts of 
BALB/c mice (n = 15) were immunized with 
SpAKKAA or with PBS/adjuvant control (mock) 
and then challenged by intravenous inocu-
lation with 5 × 106 CFU S. aureus USA300 
LAC. 30 d after infection, animals were bled 
and serum samples were analyzed for anti-
body responses to staphylococcal antigens. 
27 recombinant His6-tagged staphylococcal 
proteins were purified by Ni-NTA affinity 
chromatography and immobilized on nitro-
cellulose membrane at 2 µg. Signal intensi-
ties in sera from mice were quantified and 
normalized by infrared imaging. Data are 
the means and error bars represent ±SEM. 
Results in A and B are representative of 
three independent analyses.JEM VOL. 207, August 30, 2010  1869
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peroxidase-conjugated human IgG, Fc, or F(ab)2 fragments, IgM (The Jackson 
Laboratory),  and  vWF  (Thermo  Fisher  Scientific)  and  developed  using   
OptEIA reagent. For inhibition, plates were incubated with either naive   
rabbit F(ab)2 fragments (The Jackson Laboratory) or 10 µg ml1 of affinity- 
purified F(ab)2 fragments before ligand binding.
B cell apoptosis. 150 µg of purified protein was injected into the peritoneum of 
6-wk-old BALB/c. 4 h after injection, animals were killed and spleens removed 
and homogenized. Red blood cells were lysed in ACK buffer. White blood cells 
were stained with R-PE–conjugated anti-CD19 (eBioscience). Cells were 
washed and fixed with formalin and analyzed by FACSCanto (BD).
Antibody quantification. Nitrocellulose membrane was blotted with human/
mouse IgG (The Jackson Laboratory), SpAKKAA, and CRM197, blocked, and in-
cubated with either human or mouse sera. IRDye 700DX–conjugated anti– 
human/mouse IgG (Rockland Immunochemicals, Inc.) was used to quantify 
signal intensities from healthy human volunteers or mice using the Odyssey   
infrared imaging system (LI-COR Biosciences). Experiments with blood from 
human volunteers involved protocols that were reviewed, approved, and per-
formed under regulatory supervision of The University of Chicago’s Institu-
tional  Review  Board.  For  the  staphylococcal  antigen  matrix,  nitrocellulose 
membrane was blotted with 2 µg of a collection of Ni-NTA affinity-purified re-
combinant His6-tagged staphylococcal proteins. Signal intensities in mouse sera 
were quantified and normalized using anti-His6 antibody with the Odyssey.
Statistical Analysis. Unpaired two-tailed Student’s t tests were performed 
to analyze the statistical significance of renal abscess, ELISA, and B cell 
superantigen data.
Online supplemental material. Fig. S1 shows that SpA is a virulence factor 
for lethal infection after intraperitoneal injection of S. aureus Newman into 
BALB/c mice and that active or passive immunization with antibodies raised 
against SpAKKAA can protect against this disease. Fig. S2 shows that SpAKKAA, 
unlike wild-type SpA, does not induce B cell apoptosis in mice and that an-
tibodies raised against SpAKKAA neutralize the B cell superantigen attributes of 
SpA. Fig. S3 shows that immunization of mice with SpAKKAA prevents mul-
tiple S. aureus strains from inducing renal abscess formation in mice and that 
prior infection with S. aureus does not elicit immunity to subsequent infection 
with the same strain. Online supplemental material is available at http://www 
.jem.org/cgi/content/full/jem.20092514/DC1.
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